Stocks to Buy

This Stocks to Buy forecast is part of the Risk-Conscious Package, as one of I Know First’s equity research solutions. We determine our aggressive stock picks by screening our algorithm daily for higher volatility stocks that present greater opportunities but are also riskier. The full Risk-Conscious Package includes a daily forecast for a total of 40 stocks divided into four main categories:

• Top 10 Aggressive stocks for the long position
• Top 10 Aggressive stocks for the short position
• Top 10 Conservative stocks for the long position
• Top 10 Conservative stocks for the short position

Package Name: Aggressive Stocks Forecast
Recommended Positions: Long
Forecast Length: 1 Month (1/20/2020 – 2/20/2020)
I Know First Average: 9.63%

During the 1 Month forecasted period several picks in the Aggressive Stocks Forecast Package saw significant returns. The algorithm had correctly predicted 8 out 10 returns. The top-performing prediction in this forecast was PBYI, which registered a return of 43.47%. NVAX and HOV also performed well for this time horizon with returns of 38.33% and 12.73%, respectively. The package saw an overall yield of 9.63% versus the S&P 500’s return of 1.31% implying a market premium of 8.32%.

Puma Biotechnology, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) and PB272 (neratinib (intravenous) that are in Phase-III and Phase-II clinical trials for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, and HER2 mutation-positive solid tumors. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.